| Literature DB >> 36105966 |
Pranjal Bhuyan1, Mausumi Ganguly1, Indrani Baruah1, Gargi Borgohain1, Jnyandeep Hazarika1, Shruti Sarma1.
Abstract
In view of the recent reports of the antidiabetic effect of the black rice bran extract, an attempt has been made in the present work to evaluate the potential α-glucosidase inhibitory activity of a few selected bioactive compounds present in the pericarp of the black rice. Out of the six bioactive compounds from black rice bran selected for the study, two compounds viz. cyanidin-3-glucoside and 6'-O-feruloylsucrose were identified as novel and highly potent α-glucosidase inhibitors via their in vitro and in silico screenings. The enzyme inhibition assay was corroborated by molecular docking and molecular dynamics simulation studies. Molecular docking studies suggested high binding energies and good binding interactions of these compounds with the active site residues of the receptor protein. A good agreement was found between the results of both modes of evaluation. The experimental results proved that the black rice bran extract can show 62% of alpha glucosidase inhibiting enzyme activity as compared to that of the popular drug Acarbose. While both the docking scores and binding affinity values indicate the formation of a ligand-enzyme complex by the major components of the extract, the molecular dynamics study further indicates the stability of the complex. The pharmacokinetic (ADMET properties) studies of these active compounds also support their use as safe oral anti-diabetic drugs. Thus, the results obtained from these studies of alpha glucosidase inhibition by bioactive compounds present in black rice bran indicate that these bioactive compounds can produce significant antidiabetic activity by inhibiting the active site of the target enzyme and hence these compounds can be used as leads for the synthesis of new antidiabetic drugs. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 36105966 PMCID: PMC9373002 DOI: 10.1039/d2ra04228b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Structures of the six phytochemicals present in BRBE chosen for the study viz. cyanadin 3-O-glucoside (COG), 6′-O-feruloylsucrose (FLS), protocatechuic acid (PCA), sinapic acid (SPA), syringic acid (SYA), and p-coumaric acid (pCmA).
Fig. 2Inhibitory activity of Acarbose and black rice bran extract in ethyl acetate, methanol and hexane against alpha glucosidase enzyme.
Half-maximal inhibitory concentration (IC50) value of BRBE for inhibition of alpha-glucosidase enzyme activity
| % inhibition | IC50 (μg mL−1) | |||||
|---|---|---|---|---|---|---|
| Concentrations (μg mL−1) | ||||||
| 20 | 40 | 60 | 80 | 100 | ||
| Acarbose | 20.8 ± 0.75 | 38.6 ± 0.26 | 55.29 ± 0.70 | 68.8 ± 1.21 | 75.4 ± 0.91 | 56.42 ± 4.17 |
| Ethyl acetate | 10.6 ± 0.72 | 29.8 ± 0.26 | 51.4 ± 0.50 | 60.1 ± 1.41 | 66.7 ± 0.52 | 47.79 ± 2.28 |
| Methanolic extract | 10.2 ± 0.96 | 26.7 ± 1.50 | 48 ± 1.51 | 59 ± 4.46 | 62 ± 2.19 | 48.50 ± 0.83 |
| Hexane extract | 9.8 ± 0.36 | 24.9 ± 0.69 | 42.7 ± 0.65 | 55 ± 0.52 | 59.8 ± 1.05 | 52.80 ± 1.65 |
Fig. 3The HPLC chromatogram of the BRBE, protocatachuic acid, syringic acid and p-coumaric acid respectively.
Pharmacokinetic properties of the bioactive compounds isolated from BRBE
| Ligands | Absorption | Distribution | Metabolism | Excretion | Toxicity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caco-2 permeability | Intestinal absorption | Water solubility | VDss | BBB permeability | CNS permeability | Cytochrome P450 inhibitors | CYP2D6/CYP3A4 substrate | Renal OCT2 substrate | Total clearance | Rat LD50 | Max. tolerated dose | Hepatotoxicity | |
| COG | 0.058 | 45.392 | −2.929 | 1.464 | −1.713 | −3.813 | No | No | No | 0.522 | 2.549 | 0.562 | No |
| FLS | −0.478 | 29.911 | −1.863 | −0.186 | −1.358 | −4.977 | No | No | No | 0.715 | 2.505 | 0.174 | No |
| PCA | 0.49 | 71.174 | −2.069 | −1.298 | −0.683 | −3.305 | No | No | No | 0.551 | 2.423 | 0.814 | No |
| SPA | 0.272 | 93.064 | −2.869 | −1.11 | −0.247 | −2.663 | No | No | No | 0.718 | 2.24 | 1.193 | No |
| SYA | 0.495 | 73.076 | −2.223 | −1.443 | −0.191 | −2.701 | No | No | No | 0.646 | 2.157 | 1.374 | No |
| pCmA | 1.21 | 93.494 | −2.378 | −1.151 | −0.225 | −2.418 | No | No | No | 0.662 | 2.155 | 1.111 | No |
Molecular properties of the bioactive ligands from BRBE (Lipinki's rule)
| Ligands | Molecular weight | Log | No. of atoms | H-bond acceptor | H-bond donor | Topological polar surface area | Molecular refractivity | Predicted toxicity class |
|---|---|---|---|---|---|---|---|---|
| COG | 449.388 | 0.382 | 53 | 10 | 8 | 193.44 | 108.29 | 5 |
| FLS | 518.468 | −3.4171 | 66 | 14 | 8 | 225.06 | 116.02 | 5 |
| PCA | 154.121 | 0.796 | 17 | 3 | 3 | 77.76 | 37.45 | 4 |
| SPA | 224.212 | 1.5072 | 28 | 4 | 2 | 75.99 | 58.12 | 4 |
| SYA | 198.174 | 1.1076 | 24 | 4 | 2 | 75.99 | 48.41 | 4 |
| pCmA | 164.16 | 1.49 | 20 | 2 | 2 | 57.13 | 45.13 | 5 |
Molecular docking score, binding affinity values, no. of interacting residues, common interacting residues, and no. of hydrogen bonds for the binding of bioactive compounds of black rice bran with α-glucosidase enzyme
| Ligands | Docking score (kcal mol−1) | Binding affinity (kcal mol−1) | No. of interacting residues | No. of common interacting residues | No of H-bonds |
|---|---|---|---|---|---|
| COG | −12.872 | −92.47 | 23 | 12 | 5 |
| FLS | −11.925 | −58.91 | 24 | 13 | 10 |
| α- | −9.304 | −26.22 | 16 | 16 | 7 |
| SPA | −5.858 | −30.86 | 16 | 8 | 3 |
| PCmA | −4.382 | −15.97 | 9 | 0 | 2 |
| SYA | −4.315 | −23.29 | 16 | 13 | 2 |
| PCA | −3.773 | −8.65 | 10 | 0 | 3 |
Fig. 4Amino-acid residues in the binding pocket of α-glucosidase enzyme involved in the interactions of with (a) native ligand α-d-glucopyranose (b) COG (c) FLS (d) SYA (e) SPA (f) PCA (g) p-CmA respectively.
H-bond forming residues, π–π stacking interaction, and interacting residues along with their bond distances in the binding of bioactive compounds of black rice bran with α-glucosidase enzyme
| Compound | H-bond | π–π interactions | Amino acid residues involved in interaction | ||
|---|---|---|---|---|---|
| Residues | Bond distance (Å) | Residues | Bond distance (Å) | ||
| COG | Glu411 | 2.04 | Tyr158, Tyr72, Phe178 | 3.94, 4.19, 5.24 | Leu246, asp242, phe178, leu219, tyr72, val216, asp215, arg213, arg446, hie351, asp352, gln353, gln279, glu277, phe303, thr306, arg315, tyr316, ile440, arg442, glu411, tyr158, phe159 |
| Asp352 | 1.97 | ||||
| Gln279 | 1.73 | ||||
| Hie351 | 1.87 | ||||
| Asp215 | 1.82 | ||||
| FLS | Glu277 | 1.77 | Hip280 | 4.51 | Phe303, glu277, gln279, hip280, asp307, thr310, ser311, pro312, leu313, phe314, arg315, hie112, val101, phe178, gln182, val109, arg213, asp215, val216, arg442, asp69, tyr72, phe159, glu411 |
| Pro312 | 1.94 | ||||
| Hie122 | 2.22 | ||||
| Asp215 | 1.81 | ||||
| Asp215 | 1.79 | ||||
| Hie351 | 1.88 | ||||
| Asp69 | 1.85 | ||||
| Arg442 | 1.88 | ||||
| Glu411 | 2.56 | ||||
| Glu411 | 1.97 | ||||
| PCA | Asp242 | 1.89 | Ser240, asp242, pro312, leu313, phe314, arg315, lys156, tyr158, leu246, hip280 | ||
| Asp242 | 1.93 | ||||
| Arg315 | 2.24 | ||||
| SYA | Arg213 | 2.05 | Phe303, tyr158, phe159, asp69, tyr72, gln182, phe178, hie112, val216, asp215, arg213, asp352, hie351, asn350, gln279, glu277 | ||
| Hie315 | 2.34 | ||||
| SPA | Gln279 | 1.93 | Phe178, tyr158, phe159, arg213, val216, glu277, gln279, tyr347, asn350, asp352, gln353, phe303, arg442, glu411, tyr316, arg315 | ||
| Tyr316 | 1.85 | ||||
| Arg315 | 1.90 | ||||
| pCmA | Ser241 | 1.93 | Leu177, ser240, asp242, lys156, ser157, tyr158, tyr316, arg315, phe314 | ||
| Lys156 | 1.69 | ||||
| α- | Hie112 | 2.31 | Val109, hie112, asp69, tyr72, val216, asp215, arg213, phe303, hie351, asp352, glu277, arg446, phe159, arg442, phe178, gln182 | ||
| Asp215 | 1.66 | ||||
| Arg213 | 1.97 | ||||
| Asp352 | 1.85 | ||||
| Asp352 | 1.86 | ||||
| Arg442 | 1.72 | ||||
| Asp69 | 1.80 | ||||
Fig. 5RMSD graph of the protein ligand complex formed between COG and human α-glucosidase enzyme (PDB id: 3A4A).
Fig. 6No. of H-bonds vs. frame number graph.
Fig. 7Snapshots of COG–alpha-glucosidase enzyme complex during molecular dynamics simulation at different time periods.